ME
MEDIF.US Medipharm Labs Corp
- Market cap
- USD 18.8M
- P/E
- -
- P/B
- 0.81x
- ROE
- -4.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MEDIF.US undervalued?
Graham numberThe Graham number of Medipharm Labs Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medipharm Labs Corp fundamental analysis
No fundamental analysis for Medipharm Labs Corp yet.
Medipharm Labs Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medipharm Labs Corp
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distrib…
Full company profileMedipharm Labs Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medipharm Labs Corp annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 10.2M | 129M | 36.0M | 21.7M | 22.1M | 33.1M | 42.0M | 45.1M | 37.9M |
| Gross Profit | 0.00 | 0.00 | 3.97M | 42.9M | -44.0M | -15.2M | -1.91M | 5.86M | 12.8M | 14.0M | 15.3M |
| Operating Income | -134K | -948K | -8.03M | 6.94M | -71.0M | -43.0M | -28.8M | -17.7M | -10.9M | -8.41M | -1.89M |
| EBITDA | - | - | -214K | 9.96M | -53.4M | -38.5M | -27.1M | -10.5M | -7.52M | -6.54M | -140K |
| Net Income | -134K | -990K | -8.39M | 1.65M | -66.4M | -54.8M | -30.0M | -13.1M | -10.7M | -8.27M | -1.73M |
| EPS | - | -0.20 | -0.09 | 0.01 | -0.43 | -0.20 | -0.11 | -0.03 | -0.03 | -0.02 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 262K | 400K | 461K | 169M | 118M | 92.4M | 65.5M | 63.9M | 53.7M | 45.7M | 46.0M |
| Total Liabilities | 46.7K | 0.00 | 33.9K | 37.6M | 39.8M | 9.22M | 9.49M | 10.9M | 10.5M | 9.93M | 10.6M |
| Shareholders' Equity | 215K | 400K | 427K | 131M | 78.4M | 83.1M | 56.0M | 53.0M | 43.2M | 35.8M | 35.4M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 38.6M | 19.9M | 34.1M | 24.1M | 18.0M | 11.7M | 10.8M | 9.85M |
| Total Debt | - | 0.00 | 0.00 | - | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -54.7K | 166K | -11.1M | -25.2M | -37.8M | -13.2M | -16.1M | -12.3M | -4.86M | -5.50M | -2.52M |
| Capital Expenditure | 2.14M | 2.14M | 14.6M | 32.4M | 7.50M | 783K | 863K | 471K | 154K | 100K | 94.0K |
| Free Cash Flow | - | - | -102K | -57.7M | -45.3M | -14.0M | -16.9M | -12.8M | -5.02M | -5.60M | -2.61M |
| Ratios | |||||||||||
| ROE | -62.2% | -247.5% | -1,963.6% | 1.3% | -84.6% | -65.9% | -53.5% | -24.7% | -24.8% | -23.1% | -4.9% |
| ROA | -51.1% | -247.5% | -1,819.0% | 1.0% | -56.1% | -59.3% | -45.8% | -20.5% | -19.9% | -18.1% | -3.8% |
| Net Profit Margin | - | - | -82.2% | 1.3% | -184.3% | -252.4% | -135.6% | -39.6% | -25.5% | -18.3% | -4.6% |
| Debt to Equity | - | 0.00x | 0.00x | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medipharm Labs Corp dividends
Medipharm Labs Corp has not paid dividends in the last 9 fiscal years.
Who owns Medipharm Labs Corp
- Insiders 11.64%
- Institutions 0.00%
- Public & others 88.36%
- Shares outstanding 427M
- Free float 390M
Medipharm Labs Corp company profile
- Company name
- Medipharm Labs Corp
- Ticker
- MEDIF.US
- ISIN
- CA58504D1006
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 127
- Fiscal year end
- December
- Address
- 151 John Street, Barrie, ON, Canada, L4N 2L1
- Phone
- 705-719-7425
- Website
- medipharmlabs.com
About Medipharm Labs Corp
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower, pre-roll, and other cannabis products. In addition, the company offers cannabis related medical information and services; and cannabis clinic services for patients requiring medical cannabis education and prescriptions. MediPharm Labs Corp. was founded in 2015 and is based in Barrie, Canada.
Medipharm Labs Corp management
3- Mr. Keith StrachanCo-Founder & Chair of the Board
- Mr. Greg HunterCFO & Interim CEO
- Mr. Kirk BinnsExecutive Vice President of Global Accounts